24 Amino Acid Residues In Defined Sequence Patents (Class 530/325)
  • Patent number: 10988516
    Abstract: This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 27, 2021
    Assignee: UTI Limited Partnership
    Inventor: Pedro Santamaria
  • Patent number: 9732131
    Abstract: Compositions, methods, systems, apparatus and/or articles of manufacture are disclosed for reducing the susceptibility of a population and/or members thereof to cancer, which may include anti-cancer vaccines, components thereof which may include novopeptides, and methods relating thereto.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 15, 2017
    Assignee: CALVIRI, INC.
    Inventor: Stephen Albert Johnston
  • Patent number: 9610318
    Abstract: The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: April 4, 2017
    Assignees: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SOOKMYUNG WOMEN'S UNIVERSITY, IL-YANG PHARM CO., LTD., SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Dae Ho Cho, Sa Ik Bang, Jeong Min Park, Sun Young Yoon, Sang Yoon Kim, Ha Rum Lee, Yoo Rim Park, Juah Son
  • Patent number: 9486472
    Abstract: Methods and compositions for treating neurological damage or dysfunction are described, including methods implemented by administration of peptide inhibitors of AMPA receptor endocytosis.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: November 8, 2016
    Assignee: UNIVERSITY OF BRITISH COLUMBIA CANADA
    Inventors: Yu Tian Wang, Yushan Wang, Anthony Phillips, Lidong Liu, Yitao Liu
  • Patent number: 9302014
    Abstract: The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleotide-based therapeutics, such as polynucleotides, oligonucleotides and peptide nucleic acids. A CPPs of the invention provides a balance between good cell entry efficiency and low toxicity and comprises three contiguous domains: the central one being hydrophobic and the flanking ones consisting of arginine and aminohexanoic acid or beta-alanine residues. The hydrophobic domain contains a sequence selected from YQFLI, YRFLI, IQFLI and IRFLI.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: April 5, 2016
    Assignee: Medical Research Council
    Inventors: Michael John Gait, Andrey Alexandrovich Arzumanov, Amer F. Saleh, Matthew J. A. Wood, Corinne Betts, Taeyoung Koo
  • Patent number: 9051385
    Abstract: Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions that comprise ARF polypeptides. ARF polypeptides and ARF polypeptide-based compositions are useful in the treatment of cancer and infectious disease.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: June 9, 2015
    Assignee: DENDREON CORPORATION
    Inventors: Thomas Graddis, Reiner Laus, Michael Diegel, Damir Vidovic
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150126441
    Abstract: Nutritive proteins comprising no phenylalanine (Phe) are provided. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present a benchmark protein.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 7, 2015
    Inventors: David Arthur Berry, Brett Adam Bohigian, Nathaniel W. Silver, Michael J. Hamill, Geoffrey von Maltzahn, John F. Kramarczyk, Rajeev Chillakuru
  • Publication number: 20150125477
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: November 3, 2014
    Publication date: May 7, 2015
    Inventors: Sabrina KUTTRUFF-COQUI, Toni WEINSCHENK, Jens FRITSCHE, Steffen WALTER, Norbert HILF, Oliver SCHOOR, Colette SONG, Harpreet SINGH
  • Patent number: 9023806
    Abstract: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: May 5, 2015
    Assignees: Universite d'Angers, Institut National de la Sante et de la Recherche Medicale (Inserm), McGill University
    Inventors: Arnaud Bocquet, Joël Eyer, Alan Peterson
  • Publication number: 20150121569
    Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.
    Type: Application
    Filed: July 1, 2014
    Publication date: April 30, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNITERSITE PAUL SABATIER TOULOUSE III
    Inventors: Jean-Philippe COMBIER, Dominique LAURESSERGUES, Guillaume BECARD, Francois PAYRE, Serge PLAZA, Jerome CAVAILLE, Jerome CAVAILLE
  • Publication number: 20150119336
    Abstract: The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to the use of these substances, referred to hereinbelow as “polymers”, in particular in medicine.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Inventors: Dieter Willbold, Susanne Aileen Funke, Oleksander Brener, Luitgard Nagel-Steger, Dirk Bartnik
  • Publication number: 20150119340
    Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Publication number: 20150110797
    Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 23, 2015
    Inventors: Michal A. Rahat, Nitza Lahat, Miriam Walter, Haim Bitterman
  • Publication number: 20150110744
    Abstract: There is provided peptides for inhibiting growth of cancer cells, the peptides comprising the amino acid sequence RxKxKxxxxR wherein K and R are respectively lysine and arginine amino acid residues, each x is independently an amino acid, and 5 wherein the peptide has 50% or less amino acid sequence identity with the amino acid sequence RSKAKNPLYR (SEQ ID. No. 2). Each x amino acid may independently be an amino acid residue selected from the group consisting of alanine (A), valine (V), leucine (L), isoleucine (I), threonine (T) and serine (S) amino acid residues. There is also provided chimeric proteins incorporating a peptide of the amino acid sequence 10 RxKxKxxxxR, nucleic acids encoding for the peptide, expression vectors including a nucleic acid encoding the peptide for expression of the peptide, and methods for use of the peptide for inhibiting growth of cancer cells.
    Type: Application
    Filed: January 24, 2013
    Publication date: April 23, 2015
    Inventor: Michael Valentine Agrez
  • Patent number: 9012603
    Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 21, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin
  • Publication number: 20150104458
    Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.
    Type: Application
    Filed: August 26, 2014
    Publication date: April 16, 2015
    Applicant: Biomay AG
    Inventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
  • Patent number: 9005627
    Abstract: Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such peptides while providing all potential T cell epitopes are devoid of the three-dimensional structure of the original allergen, therefore reducing their ability to bind IgE.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: April 14, 2015
    Assignee: Anergis S.A.
    Inventors: Christophe Reymond, Francois Spertini
  • Publication number: 20150099693
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMVAX CO., LTD., GEMVAX-AS
    Inventors: Sang Jae Kim, Kyun Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 8999937
    Abstract: Polypeptide compositions that mimic the activity of glucocorticoid induced leucine zipper (GILZ) on the immune system are described. Also described is a method of treating multiple sclerosis using compositions comprising GILZ or lower molecular weight polypeptides with structural relationships to GILZ.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: April 7, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Mythily Srinivasan
  • Patent number: 8999925
    Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 7, 2015
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Jennifer S. Spence, Robert F. Garry
  • Patent number: 8987377
    Abstract: The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: March 24, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Stephanie E. Barrett, Marina Busuek, Steven L. Colletti, Robert M. Garbaccio, Erin N. Guidry, Robert A. Kowtoniuk, Jing Liao, Craig A. Parish, Rubina G. Parmar, Tao Pei, Kevin M. Schlosser, David M. Tellers, Sandra C. Tobias, Quang T. Truong, Jacob H. Waldman, Weimin Wang, J. Michael Williams
  • Patent number: 8986712
    Abstract: The present invention relates to peptides, derivatives and analogs comprising an amino acid sequence derived from the transmembrane domain of HIV gp41 protein, pharmaceutical compositions comprising same, and uses thereof for therapy of inflammatory diseases and disorders, such as T-cell and/or monocyte mediated diseases.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: March 24, 2015
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Yechiel Shai, Irun R. Cohen, Tomer Cohen
  • Patent number: 8986700
    Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: March 24, 2015
    Assignee: The Council of the Queensland Institute of Medical Research
    Inventors: David Jackson, Weiguang Zeng
  • Patent number: 8987192
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABAC1 that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: March 24, 2015
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson
  • Patent number: 8981047
    Abstract: Glucagon antagonists are provided which comprise amino acid substitutions and/or chemical modifications to glucagon sequence. In one embodiment, the glucagon antagonists comprise a native glucagon peptide that has been modified by the deletion of the first two to five amino acid residues from the N-terminus and (i) an amino acid substitution at position 9 (according to the numbering of native glucagon) or (ii) substitution of the Phe at position 6 (according to the numbering of native glucagon) with phenyl lactic acid (PLA). In another embodiment, the glucagon antagonists comprise the structure A-B-C as described herein, wherein A is PLA, an oxy derivative thereof, or a peptide of 2-6 amino acids in which two consecutive amino acids of the peptide are linked via an ester or ether bond.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: March 17, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, Bin Yang
  • Patent number: 8980844
    Abstract: A peptide having antibacterial or anti-inflammatory activity and a pharmaceutical composition containing the same as an active ingredient are described. Also, a peptide having antibacterial or anti-inflammatory activity against dental bacteria, including periodontal pathogens, and bacteria causing atopic dermatitis, and a pharmaceutical composition containing the peptide as an active ingredient are described. The inventive peptide having antibacterial or anti-inflammatory activity can be used for the treatment of both dental infectious diseases, including periodontitis, and inflammations, including arthritis.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 17, 2015
    Assignee: Nano Intelligent Biomedical Engineering Corporation Co. Ltd.
    Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee
  • Patent number: 8975371
    Abstract: The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 10, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Nantes, Chu Nantes
    Inventors: Nathalie Labarriere, Agnes Moreau-Aubry, Yann Godet
  • Publication number: 20150065384
    Abstract: The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an array comprising the nucleic acids and peptides of the invention.
    Type: Application
    Filed: October 14, 2014
    Publication date: March 5, 2015
    Inventors: Nigel J. Cairns, Robert H. Baloh, Alan Pestronk, Michael A. Gitcho, Alison M. Goate
  • Publication number: 20150065435
    Abstract: The present invention provides reagents and methods for treating dental disease.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 5, 2015
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Mehmet Sarikaya, Martha Somerman, Candan Tamerler-Behar, Hanson Fong, Hai Zhang, Mustafa Gungormus
  • Patent number: 8969524
    Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: March 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Publication number: 20150051153
    Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.
    Type: Application
    Filed: July 13, 2011
    Publication date: February 19, 2015
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
  • Publication number: 20150045291
    Abstract: The invention provides conjugates comprising a short isolated peptide coupled to a sphingolipid, the peptide comprising a sequence derived from the HIV-1 gp41. The sphingolipid-peptide conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV.
    Type: Application
    Filed: April 3, 2013
    Publication date: February 12, 2015
    Inventors: Yechiel Shai, Avraham Ashkenazi
  • Publication number: 20150045506
    Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.
    Type: Application
    Filed: March 18, 2013
    Publication date: February 12, 2015
    Applicants: UNIVERSITE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLE
    Inventors: Oleg Melnyk, Laurent Raibaut, Nathalie Ollivier
  • Patent number: 8951974
    Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3 db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: February 10, 2015
    Assignees: Menicon Co., Ltd., National University Corporation Okayama University
    Inventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
  • Publication number: 20150037362
    Abstract: The invention provides methods, compositions, and kits featuring novel RIG-I like receptor activators or inhibitors for use in preventing or treating virus infection or autoimmune disease.
    Type: Application
    Filed: July 23, 2012
    Publication date: February 5, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Jonathan C. Kagan
  • Publication number: 20150031600
    Abstract: The present invention relates to designed polypeptide biosurfactants that may be prepared by recombinant technology in commercially useful amounts and purified by simple non-chromatographic methods. The designed polypeptide biosurfactants comprise at least one stimuli-responsive amino acid residue or at least one glutamine or asparagine residue and may be useful in modulating the stability of a foam, alone or in combination with an ?-helical peptide. The designed polypeptide biosurfactant may be useful in the formation and collapse of foams in foods, beverages, pharmaceuticals, personal care products, cosmetics, cleaning products, mineral recovery, bioremediation, oil recovery and laundry products. The designed biosurfactants may also be useful in recombinant production and purification of peptides, polypeptides and proteins.
    Type: Application
    Filed: December 14, 2011
    Publication date: January 29, 2015
    Applicant: The University of Queensland
    Inventors: Anton Peter Jacob Middelberg, Mirjana Dimitrijev-Dwyer, Michael Brech
  • Publication number: 20150025016
    Abstract: The present invention relates to peptides capable of inhibiting the formation of the complex between the Asf1 histone chaperone and histones H3-H4, and to the use thereof as a drug, particularly for treating cancer.
    Type: Application
    Filed: November 16, 2012
    Publication date: January 22, 2015
    Inventors: Francoise Ochsenbein, Raphael Guerois, Albane Gaubert, Regis Courbeyrette
  • Publication number: 20150004189
    Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 1, 2015
    Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
  • Publication number: 20140377542
    Abstract: A plate with titanium dioxide on its surface, as well as its manufacturing process and uses thereof are provided. The plate comprises (A) a substrate; (B) a polydimethylsiloxane (PDMS) layer on at least one surface of the substrate; and (C) one or more aggregations of titanium dioxide particles on the polydimethylsiloxane layer. The plate is useful in the purification of phosphopeptides.
    Type: Application
    Filed: September 12, 2013
    Publication date: December 25, 2014
    Inventors: Chao-Jung Chen, Yu-Ching Liu
  • Publication number: 20140363462
    Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.
    Type: Application
    Filed: July 31, 2014
    Publication date: December 11, 2014
    Inventors: Maria ARICÒ, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
  • Patent number: 8906844
    Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: December 9, 2014
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell
  • Publication number: 20140356409
    Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 4, 2014
    Inventor: Patrick M. Schlievert
  • Publication number: 20140357577
    Abstract: The present invention concerns an inhibitor of Human Immunodeficiency Virus (HIV) fusion with, or HIV entry in, a host cell comprising at least 24, but preferably 26, contiguous amino acids; the invention also relates to a pharmaceutical composition comprising said amino acids.
    Type: Application
    Filed: December 18, 2012
    Publication date: December 4, 2014
    Inventors: Bruce Albert Malcolm, Johannes Wilhelmus J. Thuring, Christophe Francis Robert Nestor Buyck, Wim Bert Griet Schepens, Maria Aldegonda Jacoba Kriek, Wilhelmus Martinus Maria Schaaper, Jelle Wouter Slootstra, Peter Timmerman
  • Publication number: 20140349944
    Abstract: The present disclosure provides isolated integrin ?L polypeptides, such as ?7 helix polypeptides from the alpha I domain of integrin. Such polypeptides inhibit the interaction between integrin and gp96, thereby inhibiting gp96 activity. Such inhibition can be used to prevent cancer cell growth, cancer metastasis and/or inflammation.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 27, 2014
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Zihai LI, Feng HONG
  • Patent number: 8895697
    Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: November 25, 2014
    Assignee: Natimab Therapeutics S.r.l.
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • Patent number: 8895514
    Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 25, 2014
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh